Draper Associates
San Francisco early-stage VC founded by Tim Draper; co-invested in Apoha's £26.7m round.
Last refreshed: 7 June 2026 · Appears in 1 active topic
Timeline for Draper Associates
Apoha bets £26.7m on lab data
UK Startups and Innovation- Who is behind Draper Associates and what do they invest in?
- Draper Associates was founded by Tim Draper, a prominent Silicon Valley venture capitalist. The firm focuses on seed and Series A investments in transformational technology companies globally.Source: Draper Associates
- What UK companies has Draper Associates invested in?
- In June 2026, Draper Associates co-invested in Apoha's £26.7m round. Apoha builds laboratory data infrastructure for clinical and research environments and is headquartered in London.Source: event
Background
Draper Associates is a San Francisco-based early-stage venture capital firm founded by Tim Draper, one of Silicon Valley's most prominent and longest-standing venture investors. The firm focuses on seed and Series A investments in technology companies globally, with a particular emphasis on transformational or contrarian bets. Tim Draper has made high-profile investments in companies including Skype, Tesla, Hotmail, and Baidu, and has been a vocal advocate for blockchain and Cryptocurrency since early in that sector's development. Draper Associates operates alongside the broader Draper Venture Network, a global network of affiliated funds that gives it deal access across geographies.
In June 2026, Draper Associates participated as a co-investor in Apoha's £26.7m ($36m) funding round, alongside lead investor Singular, plus Seedcamp and Redalpine. Apoha builds laboratory data infrastructure for clinical environments, a sector that aligns with the Draper network's interest in deep data and healthcare technology applications. The participation represents continued transatlantic appetite for UK life-sciences software at Series A.
Draper Associates' involvement in a UK life-sciences software deal is notable given the firm's reputation for placing large single bets rather than portfolio-spreading. Its presence on the Apoha cap table alongside European co-investors signals cross-Atlantic validation of the clinical data infrastructure opportunity.